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Background: High-dose aspirin has been considered to be harmful in patients with coronary spastic angina (CSA). However, the role of low-dose 
of aspirin in CSA is still unknown. The aim of this study was to determine whether the low-dose aspirin therapy influenced the long-term clinical 
outcome in patients with CSA.
Methods: We retrospectively analyzed their clinical outcome in 169 consecutive CSA patients (60.5 ± 10.9 y, 66 females) by reviewing medical 
charts and telephone interview. Cardiac death, non-fatal myocardial infarction, unstable angina requiring hospitalization or cerebral infarction/
hemorrhage was defined as cardiovascular event.
Results: Low-dose aspirin (81 or 100 mg) was given in 100 patients with CSA. Over a mean follow-period of 4.5 years, cardiovascular event free 
survival was significantly higher in patients with aspirin compared with those without (Figure). Cox regression model showed that low-dose aspirin 
therapy was an independent predictor of better survival after adjusting for age, sex, hypertension, smoking index, existence of coronary artery 
stenosis, diabetes mellitus, family history and statin therapy (Hazard ratio: 0.443, 95% confidential interval: 0.109 to 0.772, P = 0.013). The 
beneficial effect of aspirin was substantial, irrespective of the existence of coronary stenosis.
Conclusions: Low-dose aspirin appeared to ameliorate their long-term outcome in patients with CSA. To our knowledge, this is the first 
demonstration of beneficial effect of aspirin for CSA.
